109 related articles for article (PubMed ID: 20482674)
1. Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study.
Nazarian RM; Prieto VG; Elder DE; Duncan LM
J Cutan Pathol; 2010 Apr; 37 Suppl 1():41-7. PubMed ID: 20482674
[TBL] [Abstract][Full Text] [Related]
2. FOXQ1 controls the induced differentiation of melanocytic cells.
Bagati A; Bianchi-Smiraglia A; Moparthy S; Kolesnikova K; Fink EE; Kolesnikova M; Roll MV; Jowdy P; Wolff DW; Polechetti A; Yun DH; Lipchick BC; Paul LM; Wrazen B; Moparthy K; Mudambi S; Morozevich GE; Georgieva SG; Wang J; Shafirstein G; Liu S; Kandel ES; Berman AE; Box NF; Paragh G; Nikiforov MA
Cell Death Differ; 2018 Jun; 25(6):1040-1049. PubMed ID: 29463842
[TBL] [Abstract][Full Text] [Related]
3. PRAME expression in 137 primary cutaneous melanomas and comparison with 38 related metastases.
Lo Bello G; Pini GM; Giagnacovo M; Patriarca C
Pathol Res Pract; 2023 Nov; 251():154915. PubMed ID: 37913637
[TBL] [Abstract][Full Text] [Related]
4. MITF::CREM-rearranged tumor: a novel group of cutaneous tumors with melanocytic differentiation.
Kalmykova A; Mosaieby E; Kacerovská D; Baranovska-Andrigo V; Martínek P; Smahová S; Michal M; Michal M
Virchows Arch; 2023 Oct; 483(4):569-575. PubMed ID: 37550584
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic modulation of KIT ligand in melanocytic disorders with implications for mast cell diseases.
Sevilla A; Grichnik J
Exp Dermatol; 2024 May; 33(5):e15091. PubMed ID: 38711220
[TBL] [Abstract][Full Text] [Related]
6. A UHPLC-Mass Spectrometry View of Human Melanocytic Cells Uncovers Potential Lipid Biomarkers of Melanoma.
Perez-Valle A; Abad-García B; Fresnedo O; Barreda-Gómez G; Aspichueta P; Asumendi A; Astigarraga E; Fernández JA; Boyano MD; Ochoa B
Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769491
[TBL] [Abstract][Full Text] [Related]
7. Detection of Cellular Senescence in Human Primary Melanocytes and Malignant Melanoma Cells In Vitro.
Zimmermann T; Pommer M; Kluge V; Chiheb C; Muehlich S; Bosserhoff AK
Cells; 2022 Apr; 11(9):. PubMed ID: 35563794
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive expression profiling of tumor cell lines identifies molecular signatures of melanoma progression.
Ryu B; Kim DS; Deluca AM; Alani RM
PLoS One; 2007 Jul; 2(7):e594. PubMed ID: 17611626
[TBL] [Abstract][Full Text] [Related]
9. One step at a time: Melanocytic differentiation in fusion-driven cutaneous neoplasms.
Linos K
J Cutan Pathol; 2023 Dec; 50(12):1116-1118. PubMed ID: 37844955
[TBL] [Abstract][Full Text] [Related]
10. Correlation of MET and PD-L1 Expression in Malignant Melanoma.
Song KY; Desar S; Pengo T; Shanley R; Giubellino A
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32659961
[TBL] [Abstract][Full Text] [Related]
11. Proteases in cutaneous malignant melanoma: relevance as biomarker and therapeutic target.
Fröhlich E
Cell Mol Life Sci; 2010 Dec; 67(23):3947-60. PubMed ID: 20686912
[TBL] [Abstract][Full Text] [Related]
12. Identification of DLEC1 D215N Somatic Mutation in Formalin Fixed Paraffin Embedded Melanoma and Melanocytic Nevi Specimens.
Vieira R; Simões MJ; Carmona S; Egas C; Faro C; Figueiredo A
J Skin Cancer; 2013; 2013():469671. PubMed ID: 24222856
[TBL] [Abstract][Full Text] [Related]
13. CSDE1 Intracellular Distribution as a Biomarker of Melanoma Prognosis.
Indacochea A; Guitart T; Boada A; Peg V; Quer A; Laayouni H; Condal L; Espinosa P; Manzano JL; Gebauer F
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396995
[TBL] [Abstract][Full Text] [Related]
14. Rad6 is a Potential Early Marker of Melanoma Development.
Rosner K; Adsule S; Haynes B; Kirou E; Kato I; Mehregan DR; Shekhar MP
Transl Oncol; 2014 May; 7(3):384-92. PubMed ID: 24831578
[TBL] [Abstract][Full Text] [Related]
15. Melanoma and subcutaneous adipose tissue: Role of peritumoral adipokines in disease characterization and prognosis.
Molinelli E; Ceccarelli G; Fantone S; Di Mercurio E; Gambini D; Maurizi A; Perugini J; Tossetta G; Brisigotti V; De Simoni E; Sapigni C; Rizzetto G; Campanati A; Simonetti O; Marzioni D; Offidani A
Pigment Cell Melanoma Res; 2023 Sep; 36(5):423-430. PubMed ID: 37334675
[TBL] [Abstract][Full Text] [Related]
16. Emerging clinical applications of selected biomarkers in melanoma.
Tetzlaff MT; Torres-Cabala CA; Pattanaprichakul P; Rapini RP; Prieto VG; Curry JL
Clin Cosmet Investig Dermatol; 2015; 8():35-46. PubMed ID: 25674009
[TBL] [Abstract][Full Text] [Related]
17. Cyclooxygenase 2 (COX2) and Peroxisome Proliferator-Activated Receptor Gamma (PPARG) Are Stage-Dependent Prognostic Markers of Malignant Melanoma.
Meyer S; Vogt T; Landthaler M; Berand A; Reichle A; Bataille F; Marx AH; Menz A; Hartmann A; Kunz-Schughart LA; Wild PJ
PPAR Res; 2009; 2009():848645. PubMed ID: 19639032
[TBL] [Abstract][Full Text] [Related]
18. Clinical role of PRAME expression in melanocytic tumours: A single-centre real-world retrospective study.
Hidalgo L; Peirano D; Donoso F; Villagrán S; Carrasco K; Rossi AM; Villarroel A; Del Puerto C; Villaseca-Hernández M; Navarrete-Dechent C
J Eur Acad Dermatol Venereol; 2023 Oct; 37(10):e1245-e1247. PubMed ID: 37287094
[No Abstract] [Full Text] [Related]
19. Diagnosing Cutaneous Melanocytic Tumors in the Molecular Era: Updates and Review of Literature.
Huang C; Lau TW; Smoller BR
Dermatopathology (Basel); 2024 Jan; 11(1):26-51. PubMed ID: 38247727
[TBL] [Abstract][Full Text] [Related]
20. The lipid droplet protein DHRS3 is a regulator of melanoma cell state.
Johns E; Ma Y; Louphrasitthipol P; Peralta C; Hunter MV; Raymond JH; Molina H; Goding CR; White RM
bioRxiv; 2024 Mar; ():. PubMed ID: 38586016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
